Research ExplorerPublicationsScaffold-free microtissues: differences from monolayer cultu...

Scaffold-free microtissues: differences from monolayer cultures and their potential in bone tissue engineering.

Standard

Scaffold-free microtissues: differences from monolayer cultures and their potential in bone tissue engineering. / Langenbach, Fabian; Naujoks, Christian; Smeets, Ralf; Berr, Karin; Depprich, Rita; Kübler, Norbert; Handschel, Jörg.

In: CLIN ORAL INVEST, Vol. 17, No. 1, 1, 2013, p. 9-17.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Langenbach, F, Naujoks, C, Smeets, R, Berr, K, Depprich, R, Kübler, N & Handschel, J 2013, 'Scaffold-free microtissues: differences from monolayer cultures and their potential in bone tissue engineering.', CLIN ORAL INVEST, vol. 17, no. 1, 1, pp. 9-17. <http://www.ncbi.nlm.nih.gov/pubmed/22695872?dopt=Citation>

APA

Langenbach, F., Naujoks, C., Smeets, R., Berr, K., Depprich, R., Kübler, N., & Handschel, J. (2013). Scaffold-free microtissues: differences from monolayer cultures and their potential in bone tissue engineering. CLIN ORAL INVEST, 17(1), 9-17. [1]. http://www.ncbi.nlm.nih.gov/pubmed/22695872?dopt=Citation

Vancouver

Langenbach F, Naujoks C, Smeets R, Berr K, Depprich R, Kübler N et al. Scaffold-free microtissues: differences from monolayer cultures and their potential in bone tissue engineering. CLIN ORAL INVEST. 2013;17(1):9-17. 1.

Bibtex

@article{96b4fd715c8a4d19800e447b0276857f,
title = "Scaffold-free microtissues: differences from monolayer cultures and their potential in bone tissue engineering.",
abstract = "Cell-based therapies for bone augmentation after tooth loss and for the treatment of periodontal defects improve healing defects. Usually, osteogenic cells or stem cells are cultivated in 2D primary cultures, before they are combined with scaffold materials, even though this means a loss of the endogenous 3D microenvironment for the cells. Moreover, the use of single-cell suspensions for the inoculation of scaffolds or for the direct application into an area of interest has the disadvantages of low initial cell numbers and susceptibility to unwanted cellular distribution, respectively.",
author = "Fabian Langenbach and Christian Naujoks and Ralf Smeets and Karin Berr and Rita Depprich and Norbert K{\"u}bler and J{\"o}rg Handschel",
year = "2013",
language = "English",
volume = "17",
pages = "9--17",
journal = "CLIN ORAL INVEST",
issn = "1432-6981",
publisher = "Springer",
number = "1",

}

RIS

TY - JOUR

T1 - Scaffold-free microtissues: differences from monolayer cultures and their potential in bone tissue engineering.

AU - Langenbach, Fabian

AU - Naujoks, Christian

AU - Smeets, Ralf

AU - Berr, Karin

AU - Depprich, Rita

AU - Kübler, Norbert

AU - Handschel, Jörg

PY - 2013

Y1 - 2013

N2 - Cell-based therapies for bone augmentation after tooth loss and for the treatment of periodontal defects improve healing defects. Usually, osteogenic cells or stem cells are cultivated in 2D primary cultures, before they are combined with scaffold materials, even though this means a loss of the endogenous 3D microenvironment for the cells. Moreover, the use of single-cell suspensions for the inoculation of scaffolds or for the direct application into an area of interest has the disadvantages of low initial cell numbers and susceptibility to unwanted cellular distribution, respectively.

AB - Cell-based therapies for bone augmentation after tooth loss and for the treatment of periodontal defects improve healing defects. Usually, osteogenic cells or stem cells are cultivated in 2D primary cultures, before they are combined with scaffold materials, even though this means a loss of the endogenous 3D microenvironment for the cells. Moreover, the use of single-cell suspensions for the inoculation of scaffolds or for the direct application into an area of interest has the disadvantages of low initial cell numbers and susceptibility to unwanted cellular distribution, respectively.

M3 - SCORING: Journal article

VL - 17

SP - 9

EP - 17

JO - CLIN ORAL INVEST

JF - CLIN ORAL INVEST

SN - 1432-6981

IS - 1

M1 - 1

ER -